Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 in Adult Patients With Graves' Disease (Phase 2b, Randomized, Double-Blind, Placebo-Controlled)
2025-521920-31-00Phase 2Authorised
- Sponsor
- Immunovant, Inc.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial in Graves' disease comparing IMVT-1402 arm with Placebo arm (2 arms). Planned start Nov 2025; status: authorised.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on 2025-521920-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521920-31-00.